Noha A. Bassiouny-El

Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.

Journal: BMC pharmacology & toxicology

Published: January 02, 2026

Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial.

Journal: Journal of dietary supplements

Published: December 16, 2025

The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country.

Journal: Tropical medicine and infectious disease

Published: June 27, 2025

Evaluating the role of montelukast on doxorubicin-induced cardiotoxicity in breast cancer patients.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: May 06, 2025

The impact of CBR3 (rs1056892) and ABCC1 (rs45511401) genetic polymorphisms on doxorubicin-induced cardiotoxicity and the potential role of brain natriuretic peptide as an early cardiac biomarker in breast cancer patients.

Journal: Expert opinion on drug metabolism & toxicology

Published: April 10, 2025

The potential impact of clindamycin on neurosurgery patients: a randomized controlled trial.

Journal: Inflammopharmacology

Published: March 05, 2025

Repurposing of high-dose N-acetylcysteine as anti-inflammatory, antioxidant and neuroprotective agent in moderate to severe traumatic brain injury patients: a randomized controlled trial.

Journal: Inflammopharmacology

Published: February 05, 2025

Pharmacogenomic insights: IL-23R and ATG-10 polymorphisms in Sorafenib response for hepatocellular carcinoma.

Journal: Clinical and experimental medicine

Published: November 27, 2024

Comparative Study Between the Effects of High Doses of Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction.

Journal: Cardiovascular drugs and therapy

Published: August 16, 2024

Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.

Journal: BMC cancer

Published: June 05, 2024

A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study.

Journal: British journal of clinical pharmacology

Published: January 29, 2024

Impact of CYP2D62A, CYP2D64 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients.

Journal: British journal of clinical pharmacology

Published: September 09, 2023

Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.

Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.

Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial.

Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial.

The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country.

The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country.

Evaluating the role of montelukast on doxorubicin-induced cardiotoxicity in breast cancer patients.

Evaluating the role of montelukast on doxorubicin-induced cardiotoxicity in breast cancer patients.

The impact of CBR3 (rs1056892) and ABCC1 (rs45511401) genetic polymorphisms on doxorubicin-induced cardiotoxicity and the potential role of brain natriuretic peptide as an early cardiac biomarker in breast cancer patients.

The impact of CBR3 (rs1056892) and ABCC1 (rs45511401) genetic polymorphisms on doxorubicin-induced cardiotoxicity and the potential role of brain natriuretic peptide as an early cardiac biomarker in breast cancer patients.

The potential impact of clindamycin on neurosurgery patients: a randomized controlled trial.

The potential impact of clindamycin on neurosurgery patients: a randomized controlled trial.

Repurposing of high-dose N-acetylcysteine as anti-inflammatory, antioxidant and neuroprotective agent in moderate to severe traumatic brain injury patients: a randomized controlled trial.

Repurposing of high-dose N-acetylcysteine as anti-inflammatory, antioxidant and neuroprotective agent in moderate to severe traumatic brain injury patients: a randomized controlled trial.

Pharmacogenomic insights: IL-23R and ATG-10 polymorphisms in Sorafenib response for hepatocellular carcinoma.

Pharmacogenomic insights: IL-23R and ATG-10 polymorphisms in Sorafenib response for hepatocellular carcinoma.

Comparative Study Between the Effects of High Doses of Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction.

Comparative Study Between the Effects of High Doses of Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction.

Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.

Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.

A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study.

A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study.

Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients.

Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients.

Impact of CYP2D62A, CYP2D64 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients.

Impact of CYP2D62A, CYP2D64 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients.